In a decisive regulatory measure to curb unproven medical procedures, the Union Ministry of Health and Family Welfare (MoHFW) issued a national advisory to all States and Union Territories regarding the administration of stem cell therapy. Dated September 16, 2026, the directive reiterates that stem cell therapy can only be offered as standard clinical care for a specific list of government-approved indications—primarily hematological disorders. The advisory follows explicit mandates laid down by the Supreme Court of India in the Yash Charitable Trust & Ors. v. Union of India & Ors. judgment. In a decisive regulatory intervention aimed at protecting vulnerable patients from unverified medical practices, the Union Ministry of Health and Family Welfare issued a comprehensive national directive strictly enforcing the legal framework surrounding stem cell therapies. Addressing all state regulatory bodies, health departments, and clinical establishments, the ministry clarified that stem cell procedures can only be administered as standard clinical care for specific, government-approved medical conditions. The national advisory specifically addressed the widespread commercial promotion of experimental therapies for Autism Spectrum Disorder (ASD), ruling that any therapeutic application of stem cells for autism must remain strictly restricted to approved, monitored clinical research settings. Under explicit directions aligned with landmark Supreme Court mandates, state medical councils and health directors have been authorized to institute immediate disciplinary actions, revoke clinical registrations, and prosecute unregistered practitioners offering unauthorized commercial treatments. Medical researchers, bioethics experts, and patient advocacy organizations hailed the regulatory directive as an essential safeguard, emphasizing that enforcing strict scientific compliance ensures clinical safety while preserving legitimate, ethical biomedical innovation across domestic healthcare institutions. Addressing growing concerns over private clinics promoting experimental remedies to vulnerable families, the Health Ministry explicitly clarified that any therapeutic use of stem cells for Autism Spectrum Disorder (ASD) remains strictly experimental. Such interventions must operate solely within regulated clinical trials approved by competent authorities in accordance with the National Guidelines for Stem Cell Research, 2017, framed jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT). Commercial promotion, marketing, or routine clinical administration of stem cell therapies for ASD without statutory clearance is illegal. Reinforcing the Ministry's directive, the National Medical Commission (NMC) issued an accompanying advisory warning medical practitioners that the unauthorized administration, prescription, promotion, or advertising of stem cell therapy beyond approved indications constitutes professional misconduct. State Medical Councils have been instructed to investigate reported violations and institute disciplinary actions, including license suspensions. Additionally, state and district regulatory authorities hold statutory power under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010, to seal non-compliant facilities, cancel clinical registrations, and impose heavy monetary penalties.